Publications by authors named "Sarah Elizabeth O'Donnell"
Background & Aims: Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions.
Methods: Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level.
Background & Aims: Several symptoms impair the quality of life (QoL) of patients with primary biliary cholangitis (PBC). They are reported to vary significantly in different countries. Aim of our study was to explore whether there is a geographical clustering that accounts for symptoms in PBC.
View Article and Find Full Text PDFPrimary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are autoimmune cholangiopathies characterized by limited treatment options. A more accurate understanding of the several pathways involved in these diseases has fostered the development of novel and promising targeted drugs. For PBC, the characterization of the role of farnesoid X receptor (FXR) and perixosome-proliferator activated receptor (PPAR) has paved the way to several clinical trials including different molecules with choleretic and antinflammatory action.
View Article and Find Full Text PDFArticle Synopsis
- Primary biliary cholangitis and primary sclerosing cholangitis are uncommon liver diseases that primarily impact the bile ducts, and there is still much to learn about their causes.
- Due to limited understanding, treatment options have historically been scarce, but new therapies are emerging that could improve patient care.
- This review focuses on summarizing research into new potential treatments for these conditions and explores how these advancements might transform existing approaches to treatment.